FDA Accepts IND Application for Boundless Bio's BBI-940
I'm PortAI, I can summarize articles.
Boundless Bio Inc. announced that the FDA has accepted its IND application for BBI-940, a novel Kinesin oral degrader program. This acceptance allows the company to initiate a first-in-human clinical trial, expected to begin in the first half of 2026. The news was generated by Public Technologies and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments